About wave life sciences ltd - WVE
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
WVE At a Glance
Wave Life Sciences Ltd.
Marina One East Tower
Singapore, Central Singapore 018936
| Phone | 65-6236-3388 | Revenue | 42.73M | |
| Industry | Biotechnology | Net Income | -204,378,000.00 | |
| Sector | Health Technology | Employees | 317 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
WVE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 67.102 |
| Price to Book Ratio | 6.154 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.091 |
| Enterprise Value to Sales | 53.611 |
| Total Debt to Enterprise Value | 0.008 |
WVE Efficiency
| Revenue/Employee | 134,785.489 |
| Income Per Employee | -644,725.552 |
| Receivables Turnover | 33.485 |
| Total Asset Turnover | 0.086 |
WVE Liquidity
| Current Ratio | 6.467 |
| Quick Ratio | 6.467 |
| Cash Ratio | 6.333 |
WVE Profitability
| Gross Margin | 79.282 |
| Operating Margin | -504.091 |
| Pretax Margin | -478.335 |
| Net Margin | -478.335 |
| Return on Assets | -41.259 |
| Return on Equity | -54.968 |
| Return on Total Capital | -37.57 |
| Return on Invested Capital | -53.031 |
WVE Capital Structure
| Total Debt to Total Equity | 3.376 |
| Total Debt to Total Capital | 3.266 |
| Total Debt to Total Assets | 2.782 |
| Long-Term Debt to Equity | 1.814 |
| Long-Term Debt to Total Capital | 1.729 |